These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36031856)

  • 41. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
    Chen Z; Tighiouart M; Kowalski J
    Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
    Tighiouart M; Cook-Wiens G; Rogatko A
    J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.
    Zhou Y; Lin R; Lee JJ; Li D; Wang L; Li R; Yuan Y
    Stat Med; 2022 May; 41(11):1918-1931. PubMed ID: 35098585
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents.
    Braun TM; Wang S
    Biometrics; 2010 Sep; 66(3):805-12. PubMed ID: 19995354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
    Li P; Liu R; Lin J; Ji Y
    J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
    He W; Liu J; Binkowitz B; Quan H
    Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Bayesian dose-finding design for outcomes evaluated with uncertainty.
    Schipper MJ; Yuan Y; Taylor JM; Ten Haken RK; Tsien C; Lawrence TS
    Clin Trials; 2021 Jun; 18(3):279-285. PubMed ID: 33884907
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy.
    Jiang L; Li R; Yan F; Yap TA; Yuan Y
    Contemp Clin Trials; 2021 May; 104():106338. PubMed ID: 33711459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.
    Pallmann P; Wan F; Mander AP; Wheeler GM; Yap C; Clive S; Hampson LV; Jaki T
    Clin Trials; 2020 Apr; 17(2):147-156. PubMed ID: 31856600
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
    Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
    Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.
    Kojima M
    BMC Med Res Methodol; 2022 Apr; 22(1):97. PubMed ID: 35382745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bayesian adaptive designs in single ascending dose trials in healthy volunteers.
    Guédé D; Reigner B; Vandenhende F; Derks M; Beyer U; Jordan P; Worth E; Diack C; Frey N; Peck R
    Br J Clin Pharmacol; 2014 Aug; 78(2):393-400. PubMed ID: 24528176
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimization of dose selection using multiple surrogates of toxicity as a continuous variable in phase I cancer trial.
    Lee SY; Munafo A; Girard P; Goteti K
    Contemp Clin Trials; 2022 Feb; 113():106657. PubMed ID: 34954097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Bayesian design for phase I cancer therapeutic vaccine trials.
    Wang C; Rosner GL; Roden RBS
    Stat Med; 2019 Mar; 38(7):1170-1189. PubMed ID: 30368868
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Phase I/II trial design when response is unobserved in subjects with dose-limiting toxicity.
    Braun TM; Kang S; Taylor JM
    Stat Methods Med Res; 2016 Apr; 25(2):659-73. PubMed ID: 23117408
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
    Guo B; Li Y
    BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
    Zhang L; Yuan Y
    Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.